2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1335

Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis
Abstract Number: 1336

Functional, Radiographic and Serologic Correlates of Anti-SSA52 Kd – Associated Interstitial Lung Disease
Abstract Number: 1337

Myocardial Fatty Acid Metabolism and Perfusion Mismatch in Scintigraphy Predicts Worse Prognosis in Clinically Amyopathic Dermatomyositis
Abstract Number: 1338

Validation of the Diagnostic Accuracy of Myositis-Related Antibodies in a Large Patient-Cohort
Abstract Number: 1339

Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement
Abstract Number: 1340

Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome
Abstract Number: 1341

Autoantibodies to Mi-2 Alpha and Mi-2 Beta in Patients with Myositis
Abstract Number: 1342

Myositis Specific Antibodies Measured Using a Novel Particle Based Multi-Analyte Assay Resemble Myositis Subsets By Principle Component Analysis
Abstract Number: 1343

A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy
Abstract Number: 1344

Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States
Abstract Number: 1345

Association of HLA-DRB1*0301 with Antisynthetase Syndrome in Spanish Patients
Abstract Number: 1346

Anti-NT5c1A Autoantibodies As Biomarkers in Inclusion Body Myositis
Abstract Number: 1347

A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 1348

Quantitative High Throughput Screening of Small Molecules to Inhibit Interferon-Stimulated Major Histocompatibility Complex Class I in Myositis Muscle
Abstract Number: 1349

Rnaseq of Peripheral Blood Mononuclear Cells from Juvenile Dermatomyositis, Necrotizing Myopathy and Controls Are an Aid in Diagnosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].